Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10901038 | 1.00 | KDM4E (0.65) | KDM4EGAAS1PR1THRATHRB | |
| Hydrochloric Acid SCHEMBL10899527 | 0.99 | KDM4E (0.63) | KDM4EGAAS1PR1THRATHRB | |
| SCHEMBL1280837 | 0.99 | KDM4E (0.62) | KDM4EGAAS1PR1THRATHRB | |
| SCHEMBL4238787 | 0.94 | KDM4E (0.56) | KDM4EGAAS1PR1THRATHRB | |
| SCHEMBL4237793 | 0.89 | DRD2 (0.53) | KDM4EGAAS1PR1THRATHRB | |
| SCHEMBL1305865 | 0.88 | DRD2 (0.65) | KDM4EGAAUSP2DRD2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1841012 | 0.87 | DRD2 (0.63) | KDM4EGAAUSP2DRD2SIGMAR1 | |
| SCHEMBL10901028 | 0.84 | KDM4E (0.59) | KDM4EGAATHRATHRBKCNH2 | |
| SCHEMBL1663641 | 0.84 | DRD2 (0.54) | KDM4EKCNH2USP2DRD2 | |
| SCHEMBL10901455 | 0.83 | S1PR1 (0.64) | KDM4EGAAS1PR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296579-A1 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | CORNELL UNIVERSITY (US) | 2022-09-22 | — | — | US | disclosed |
| US-11191755-B2 | Compositions and methods for providing cardioprotective effects | CORNELL UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11160769-B2 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists | CORNELL UNIVERSITY (US) | 2021-11-02 | — | — | US | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1907347-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | Arcadia Pharmaceuticals Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296579-A1 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | RARB, RARG, RARA | KDM4E 4325/4885GAA 2453/4885S1PR1 1216/4885 |
| US-11191755-B2 | Compositions and methods for providing cardioprotective effects | RARB, RARG, RARA | KDM4E 4325/4885GAA 2453/4885S1PR1 1216/4885 |
| US-11160769-B2 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists | RARA, RARG, RXRA | KDM4E 4533/4885GAA 336/4885S1PR1 2320/4885 |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | RARB, RARA, RARG | KDM4E 4405/4885GAA 789/4885S1PR1 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.